Visium, a Prilly-based AI firm, has successfully secured its first institutional funding round, marking a significant milestone in its mission to scale AI solutions within regulated industries.
The funding round, which remains undisclosed, was co-led by Columbus Venture Partners and Concentric, attracting notable angel investors from the AI sector. Visium, founded in 2018 and operating without external funding until now, specializes in delivering AI-driven solutions tailored for the pharmaceutical, life sciences, and specialty chemicals sectors. With a team of 100 experts, the company has implemented over 250 AI solutions for major clients, including Roche and Novartis, emphasizing a holistic, AI-native approach to business processes.
The newly acquired capital will facilitate Visium's expansion into European and U.S. markets. Additionally, the company is strengthening its governance by appointing new members to its Board and Advisory Board, enhancing its scientific and commercial capabilities. Recognized by the Financial Times as one of Europe’s fastest-growing companies, Visium is poised for substantial growth in the evolving landscape of AI in regulated industries.
Located at the unlimitrust campus, Visium benefits from an ecosystem focused on trust and transparency, which is crucial for its operations in data-sensitive environments. This strategic positioning not only supports its mission but also aligns with the broader goals of the Economy of Trust initiative, fostering innovation in digital trust and cybersecurity.